/SER
SER Stock - Serina Therapeutics, Inc.
Healthcare|BiotechnologyNYSE
$2.75+3.50%
+$0.09 (+3.50%) • Dec 19
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.2
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SER
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.72 – $2.78
TARGET (TP)$3.16
STOP LOSS$2.53
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.06
52W High$7.92
52W Low$2.59
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $56,000 | $3.15M | $500,000 | $3.04M | $54,000 |
| Gross Profit | $-138,000 | $3.06M | $500,000 | $3.04M | $-1,227,000 |
| Gross Margin | -246.4% | 97.1% | 100.0% | 100.0% | -2272.2% |
| Operating Income | $-17,048,000 | $-3,129,000 | $-2,270,368 | $-1,631,508 | $-10,407,000 |
| Net Income | $-11,141,000 | $5.27M | $-2,682,108 | $-1,264,703 | $-10,865,000 |
| Net Margin | -19894.6% | 167.1% | -536.4% | -41.6% | -20120.4% |
| EPS | $-1.51 | $0.63 | $-2.49 | $-8.05 | $-10.14 |
Company Overview
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$15
Average Target
↑ 445.5% Upside
Now
$15
Low
$15
Average
$15
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 14th 2025 | H.C. Wainwright | Initiation | Buy | $15 |
Earnings History & Surprises
SERBeat Rate
50%
Last 4 quarters
Avg Surprise
-55.6%
EPS vs Estimate
Beats / Misses
2/2
Last 12 quarters
Latest EPS
$-0.45
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
-164.3%
$-0.27vs$0.42
Q2 25
+21.0%
$-0.49vs$-0.62
Q3 25
-83.3%
$-0.66vs$-0.36
Q4 25
+4.3%
$-0.45vs$-0.47
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2026 | Nov 9, 2026 | — | — | — | — |
Q3 2026 | Aug 3, 2026 | — | — | — | — |
Q1 2026 | Mar 23, 2026 | $-0.42 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.47 | $-0.45 | +4.3% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.36 | $-0.66 | -83.3% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.62 | $-0.49 | +21.0% | ✓ BEAT |
Q1 2025 | Mar 24, 2025 | $0.42 | $-0.27 | -164.3% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | — | $0.13 | — | — |
Q3 2024 | Aug 9, 2024 | — | $0.51 | — | — |
Q2 2024 | May 14, 2024 | — | $-3.38 | — | — |
Q1 2024 | Mar 22, 2024 | — | $-3.20 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.14 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-5.01 | — | — |
Q1 2023 | Mar 30, 2023 | — | $-3.04 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-2.51 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-2.26 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-2.43 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-2.51 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-2.00 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-1.81 | — | — |
Latest News
Serina Therapeutics Submits Complete Response To FDA Clinical Hold Letter For SER-252, Lead Program For Advanced Parkinson's Disease
➖ NeutralBenzinga•Dec 10, 2025, 09:34 PM
Serina Therapeutics Submitted Complete Response To FDA Clinical Hold Letter For SER-252 Program
➖ NeutralBenzinga•Dec 10, 2025, 09:20 PM
Serina Therapeutics Q3 EPS $(0.45) Beats $(0.53) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 11:13 AM
The FDA Placed A Clinical Hold On Serina Therapeutics' Investigational New Drug Application For SER-252, Serina's Lead Development Program For Advanced Parkinson's Disease, And Requested Additional Information Related To A Commonly Used Excipient In The Formulation
📉 NegativeBenzinga•Nov 3, 2025, 11:11 AM
Serina Therapeutics Draws First $5M Tranche From Previously Announced $20M Financing Agreement To Support The Planned Registrational Trial Of SER-252 For Treating Advanced Parkinson's Disease, Using Serina's POZ Platform Drug Optimization Technology
📈 PositiveBenzinga•Oct 6, 2025, 08:19 PM
On September 9, 2025 Serina Therapeutics Secures Up To $20M In Milestone-Linked Convertible Note From Director Gregory H. Bailey
📈 PositiveBenzinga•Sep 15, 2025, 08:04 PM
Serina Therapeutics Secures Up To $20M In Financing To Advance SER-252 Trial In Parkinson's Disease, With Potential For Additional $20M Through Warrant Issuance
📈 PositiveBenzinga•Sep 9, 2025, 07:25 PM
HC Wainwright & Co. Reiterates Buy on Serina Therapeutics, Maintains $15 Price Target
📈 PositiveBenzinga•Aug 28, 2025, 11:13 AM
Market-Moving News for August 26th
➖ NeutralBenzinga•Aug 26, 2025, 11:22 AM•Also: ,
Serina Therapeutics shares are trading higher after the company announced the FDA has provided written feedback supporting the advancement of SER-252.
📈 PositiveBenzinga•Aug 25, 2025, 08:17 PM
Serina Therapeutics Says FDA Written Feedback Supports Advancing SER-252 In Registrational Clinical Study Program In Advanced Parkinson's Under 505(b)(2) NDA Pathway; IND Filing Planned For Q4 2025
📈 PositiveBenzinga•Aug 25, 2025, 08:07 PM
Frequently Asked Questions about SER
What is SER's current stock price?
Serina Therapeutics, Inc. (SER) is currently trading at $2.75 per share. The stock has moved +3.50% today.
What is the analyst price target for SER?
No analyst price targets are currently available for this stock.
What sector is Serina Therapeutics, Inc. in?
Serina Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is SER's market cap?
Serina Therapeutics, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does SER pay dividends?
No, Serina Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
GNTA
Genenta Science S.p.A.
$1.45
Mkt Cap: $0.0B
GRCE
Grace Therapeutics, Inc.
$3.40
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
JUNS
Jupiter Neurosciences, Inc.
$1.10
Mkt Cap: $0.0B
SKYE
Skye Bioscience, Inc.
$0.93
Mkt Cap: $0.0B
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$1.41
Mkt Cap: $0.0B
XFOR
X4 Pharmaceuticals, Inc.
$3.60
Mkt Cap: $0.0B
Explore stocks similar to SER for comparison